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Abstract: The field of endoscopy has revolutionized the diagnosis and treatment of 
  gastrointestinal (GI) diseases in recent years. Besides the ‘traditional’ endoscopic   procedures 
(esophagogastroduodenoscopy, colonoscopy, flexible sigmoidoscopy, and endoscopic retrograde 
cholangiopancreatography), advances in imaging technology (endoscopic ultrasonography, 
  wireless capsule endoscopy, and double balloon enteroscopy) have allowed GI specialists to detect 
and manage disorders throughout the digestive system. This article reviews various   endoscopic 
procedures and provides up-to-date endoscopic indications based on the   recommendations of 
American Society for Gastrointestinal Endoscopy and American Cancer Society for primary 
care providers in order to achieve high-quality and cost-effective care.
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Introduction
Open access endoscopy (OAE) is becoming more common due to the cost-driven health 
care system. It allows general practitioners to schedule elective common endoscopic 
procedures without prior specialty consultation. Endoscopies ‘generally not indicated’ 
are accounted for 49% when the examination is prescribed by general practitioners 
compared to 14% by endoscopists.1 Because of this disparity, it is critical for primary 
care physicians to have a thorough understanding of endoscopic indications. The 
purpose of this article is twofold: 1) to provide up-to-date endoscopic indications for 
primary care physicians so that only ‘indicated’ procedures are performed in order to 
avoid unnecessary complications and cost and 2) to familiarize primary practitioners 
with new endoscopic procedures in order to promote closed communication with 
gastrointestinal (GI) specialists (Table 1). The following information is based on the 
American Society for Gastrointestinal Endoscopy (ASGE) and American Cancer 
Society (ACS) recommendations.
Definition of GI endoscopic procedures
esophagogastroduodenoscopy
Esophagogastroduodenoscopy (EGD) is a procedure that visualizes the mucosal sur-
faces of the esophagus, stomach, and proximal duodenum. It allows both diagnostic 
and therapeutic functions. The gastroscope is used for EGD. It is a forward-viewing 
instrument and consists of a control head with valves for air insufflations and suction, 
an instrument channel for biopsy, an insertion length, and a bending length at the end of International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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the scope. Patients should be kept nil per os (NPO) 6 h before 
the procedure. In   preparation for EGD, the patient lies on the 
left side with the head   resting on a pillow. A mouthguard is 
placed between the teeth to prevent biting on the endoscope. 
Then the gastroscope is inserted into the mouth, down to the 
esophagus, stomach, and ultimately ending in the second 
part of the duodenum. After this maneuver, the endoscope is 
withdrawn for further inspection of the GI   lining. The fundus 
is examined by retroflexing the gastroscope’s tip to resemble 
the J-shape. Any abnormal lesions should be biopsied. Most 
GI endoscopic procedures (EGD and colonoscopy) are 
performed under conscious sedation. The patient is able to 
respond to verbal or tactile stimulation. Combinations of 
benzodiazepines (midazolam and diazepam) and opioids 
(meperidine and fentanyl) are used for sedation.2
endoscopic retrograde 
cholangiopancreatography
Endoscopic retrograde cholangiopancreatography (ERCP) 
is a technique that combines endoscopy and fluoroscopy to 
diagnose and to treat biliary or pancreatic ductal diseases. 
Similar to EGD, an endoscope is inserted through the mouth 
down into the duodenum. Instead of using a forward-viewing 
gastroscope as in EGD, a side-viewing duodenoscope is used 
for accurate identification of the ampulla of Vater, the opening 
of the common bile duct (CBD) and pancreatic duct (PD). 
When the ampulla is identified, a catheter is inserted through 
the ampulla into the CBD and/or PD. Radiocontrast dye is 
then injected into these ducts for real-time visualization by 
fluoroscopy. Fluoroscopy uses X-ray to look for strictures, 
blockages, or ductal leakages, and it guides therapeutic pro-
cedures. The bowel preparation is similar to EGD. However, 
because of longer duration, more sedatives than the standard 
benzodiazepines/opioid agents are needed for patient comfort. 
General anesthesia with propofol has demonstrated to be more 
effective than the above combinations in complex ERCP.2
endoscopic ultrasonography
Endoscopic ultrasonography (EUS) uses a high-frequency 
ultrasound transducer that is incorporated into the tip of the 
endoscope to provide high-resolution images of the GI wall 
and adjacent structures. EUS-guided fine needle aspiration 
(EUS-FNA) is a technique using a thin needle under the 
ultrasonographic guidance to obtain an aspirate of the   tissue. 
In addition, other therapeutic procedures, such as EUS-
guided drainage and EUS-guided celiac plexus blockage, 
can be performed under the guidance of real-time ultrasound. 
For upper EUS, bowel preparation is similar to EGD; for 
Table 1 A summary of appropriate indications for endoscopy
Endoscopic procedures Indications
eGD Achalasia
Barrett’s esophagus
Caustic injury
esophageal cancer
esophageal strictures
esophageal varices
Foreign bodies
Gastric epithelial polyps
Peptic ulcer disease
GeRD
Gastric cancer
Ampullary adenoma
NDA
FAP/HNPCC
Inflammatory bowel disease
PeG
Upper GI bleeding
Obscure GI bleeding
Pernicious anemia
Bariatric weight loss surgery
eRCP Choledocholithiasis
Benign biliary strictures/leaks
Pancreatic ductal leaks
Sphincter of Oddi dysfunction
Recurrent acute pancreatitis
Chronic pancreatitis
Pancreatic fluid collections
Bariatric weight loss surgery
IPMN
Ampullary adenoma
Cholangiocarcinoma
Pancreatic malignancy
eUS esophageal/colorectal cancer
Gastric carcinoma/lymphoma
Mediastinal adenopathy
Pancreatic malignancy
Pancreatic cystic lesions
Submucosal tumors
Ampullary adenoma/NDA
Ampullary carcinoma
Inflammatory bowel disease
wCe/DBe Obscure GI bleed 
Colonoscopy ACPO
Chronic diarrhea
Ampullary adenoma/NDA
Inflammatory bowel disease
Colorectal screening/surveillance
Colorectal cancer
Constipation
Lower GI bleeding
Flexible sigmoidoscopy Colorectal screening
Young patients with colonic disease
Fulminant colitis
Abbreviations: eGD, esophagogastroduodenoscopy; eRCP, endoscopic retrograde 
cholangiopancreatography; eUS, endoscopic ultrasonography; wCe/DBe, wireless 
capsule  endoscopy/double  balloon  enteroscopy;  GERD,  gastroesophageal  reflux 
disease; NDA, nonampullary duodenal adenoma; FAP/HNPCC, familial adenomatous 
polyposis/hereditary nonpolyposis colorectal cancer; PeG, percutaneous endoscopic 
gastrostomy; GI, gastrointestinal; IPMN, intraductal papillary mucinous neoplasm; 
ACPO, acute colonic pseudo-obstruction.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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lower EUS, it is similar to colonoscopy (will be discussed 
under ‘Colonoscopy’). More sedatives and analgesics may 
be required because these procedures are longer than EGD 
and colonoscopy.3
Colonoscopy
Colonoscopy allows for examination of the entire large 
bowel. The colonoscope is a forward-viewing instrument 
and has similar features to the gastroscope. As the patient 
lies on the left side, the endoscope is inserted through the 
anus, up the rectum, colon, and ultimately the terminal ileum. 
A thorough inspection is often done upon withdrawal of the 
colonoscope. Suspicious lesions are cauterized or removed 
for histopathology studies. Three accepted bowel prepara-
tions are polyethylene glycol (PEG), aqueous sodium phos-
phate (NaP), and tablet NaP. With the glycol-based product, 
patients either drink 4 L of PEG (Colyte®, GoLytely®) in one 
dose the day before the procedure or in divided doses (3 L 
the evening before and 1 L the morning of the procedure). 
The latter regimen is better tolerated. With the aqueous form, 
patients may take two doses of 30–45 mL of NaP (Fleet®) 
(at least 10–12 h apart) along with plenty of fluids to prevent 
dehydration because NaP osmotically draws plasma water 
into the bowel lumen to promote cleansing. The tablet NaP 
(Visicol®) is in a pill form that has the same salt doses as 
found in the solution without the unpleasant taste. It is also 
formulated to limit the volume of liquid required. The total 
dose is 32–40 tablets (20 on the evening before the procedure 
and 12–20 tablets 3–5 h before the colonoscopy). There 
are a few caveats with NaP laxative. It should be avoided 
in patients with congestive heart failure, renal impairment, 
and gut dysmotility due to significant fluid and electrolyte 
shifts. In addition, nonspecific aphthoid-like mucosal lesions 
have been associated with NaP. If a diagnosis of inflamma-
tory bowel disease (IBD) is being considered, NaP should 
be avoided. Similar to EGD, conscious sedation is used for 
patient comfort.4
wireless capsule endoscopy
Until the introduction of wireless capsule endoscopy (WCE) 
in 1990s, diagnosing small bowel diseases was a challenge. 
Former techniques (Sonde enteroscopy and intraopera-
tive enteroscopy) had many limitations and complications 
and were also associated with high mortality rate. WCE is 
purely a diagnostic tool. The system consists of a disposable 
‘video-recorder’ capsule, a 7-h battery that allows images 
transmission to a data recorder that is carried around the 
patient’s waist, and a computer workstation with proprietary 
software that reviews and interprets the results. WCE can 
be performed in an ambulatory outpatient setting. Without 
sedation, the capsule is ingested after a 10–12-h fasting 
period and moves through the small intestine by peristalsis. 
Although bowel preparation is not required, some centers 
advocate bowel catharsis for improved visualization of the 
small bowel. At present, studies yield conflicting results and 
no consensus has been reached.5
Double balloon enteroscopy
While CE provides only a diagnostic workup, double balloon 
enteroscopy (DBE) allows for both diagnostic and therapeutic 
capabilities. DBE enables direct visualization of the small 
bowel by the push-and-pull technique with two balloons 
under fluoroscopic guidance. The system consists of a video 
endoscope, a flexible overtube, which covers the endoscope 
and enables it to slide freely, and two latex balloons that are 
inflated and deflated by a pressure-controlled pump system. 
The balloons are attached to the tip of the enteroscope and 
the overtube. The procedure is as follows:
1.  The overtube balloon is inflated to ‘grip’ on the bowel 
lining.
2.  The enteroscope is advanced as far as possible with its 
balloon deflated.
3.  The enteroscope balloon is inflated to stabilize its 
position.
4.  The overtube balloon is deflated and moved to the 
  enteroscope balloon’s tip.
The whole process (steps 1–4) is repeated.
DBE can be performed from the oral route, the anal 
route, or both. For the oral approach, the patient is kept NPO 
for at least 6 h. For the anal approach, bowel cleansing is 
similar to colonoscopy. Total enteroscopy is not possible 
in a single procedure, and it is usually terminated when 
abnormalities are found and treated. Due to the lengthy 
procedure (70–80 min), general anesthesia is preferred.6 
Serious complications of DBE are pancreatitis (0.3%)7 and 
bowel perforation (3.4%).8
Flexible sigmoidoscopy
Instead of examining the entire colon, flexible sigmoidos-
copy (FS) only inspects the rectum, sigmoid, and descending 
colon. Although the sigmoidoscope is shorter, it shares many 
similar designs with the colonoscope. Since no sedation is 
required, the procedure can be performed in office-based set-
tings by nurses or physician assistants. For bowel preparation, 
two Fleet enemas are adequate. Patients with active colitis 
or diarrhea do not need bowel preparation. After placing the International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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patient in left lateral decubitus position, the scope is inserted 
into the rectum through the anus and is ascended until 40 cm 
is reached for a high-quality exam in colorectal cancer (CRC) 
screening. Polyps are biopsied and sent to pathology lab.
Indications for EGD
Achalasia
Achalasia is an esophageal motility disorder. In this con-
dition, the smooth muscle of the esophagus has impaired 
peristalsis, and the lower esophageal sphincter (LES) fails 
to relax   properly in response to swallowing. Some achalasia 
cases result from esophageal cancer or Chagas disease, a 
lower esophageal condition that is infected by a parasite, 
Trypanosoma cruzi. However, the cause for most achalasia 
is unknown. Symptoms include dysphagia, regurgitation 
of undigested food, coughing, and weight loss. Esophageal 
manometry is the ‘gold standard’ for diagnosing   achalasia.9 
EGD is required to exclude esophageal cancer at the gas-
troesophageal junction before therapeutic interventions. The 
treatment goal is to reduce the LES pressure. This can be 
accomplished with pneumatic balloon dilators,   botulinum 
toxin injection, or surgery as the last-line intervention 
strategy.
Barrett’s esophagus
Barrett’s esophagus is an acquired premalignant condition 
resulting from gastroesophageal reflux disease (GERD). 
It is marked by the presence of columnar epithelia in the 
lower esophagus, replacing the normal squamous epithelium. 
Compared to the normal population, patients with Barrett’s 
esophagus have 30–125 times the risk of developing esopha-
geal adenocarcinoma.10 However, screening and surveillance 
are currently still controversial. Currently, the ASGE makes 
the following recommendations:11
1.  Screening for Barrett’s esophagus: Screening EGD 
should be considered in selected patients with chronic, 
long-standing GERD (.5 years). After a negative screen-
ing examination, further screening endoscopy is not 
necessary.
2.  Barrett’s esophagus with no dysplasia: For patients 
with established diagnosis of Barrett’s esophagus, 
after two consecutive examinations with no dysplasia 
within 1 year, additional surveillance can be extended 
to 3 years.
3.  Barrett’s esophagus with low-grade dysplasia: For 
patients with low-grade dysplasia (LGD), an EGD should 
be performed at 6 months from LGD diagnosis with 
concentrated biopsies in the area of dysplasia. If LGD is 
confirmed, then annual surveillance endoscopy is recom-
mended thereafter as long as dysplasia persists.
4.  Barrett’s esophagus with high-grade dysplasia: For 
patients with high-grade dysplasia (HGD), they can 
either elect to have treatment (photodynamic/thermal 
ablation or esophagectomy) or continue with surveillance. 
Patients who choose surveillance will have an EGD every 
3 months for at least 1 year. After 1 year of no cancer 
detection and two consecutive endoscopies (at 3-month 
intervals) show no dysplastic changes, the surveillance 
interval can be extended.
5.  Barrett’s esophagus with indeterminate dysplasia: There 
may be a component of inflammation due to GERD. As a 
result, a repeat EGD should be performed after 8 weeks 
of acid-suppression therapy.
Caustic injury
Caustic injury is resulted from accidental or intentional 
ingestion of alkaline or acidic substances that include 
drain   cleaners and other household cleaning products. 
  Self-poisoning with these chemicals is common in Asia. 
The result is intense damage to the esophagus and stomach, 
often producing perforation. Late sequelae are stricture and 
squamous cell carcinoma. The incidence of carcinoma has 
been estimated to be 1%–4%. After 12–20 years of injury, 
EGD is recommended. Subsequently, surveillance should 
not be more than every 1–3 years.11
esophageal cancer
Approximately 13,000 cases of esophageal cancer are diag-
nosed annually in the United States. Adenocarcinoma of 
the esophagus has one of the fastest rising incidence rates 
of any malignancy. EGD is the primary method for direct 
visualization and allows the endoscopist to obtain multiple 
biopsies. The classic endoscopic appearance is an ulcerated 
mass projecting from a rigid, aperistaltic segment of the 
esophagus.12 EGD also plays an important role in detecting 
recurrence and in treating esophageal cancer.13
esophageal strictures
Sixty to seventy percent of all esophageal strictures are 
caused by GERD, and the remaining strictures are   secondary 
to Schatzki’s ring (a ring found in lower esophagus causing 
dysphagia), esophageal cancer, radiation therapy, esophageal 
surgery, eosinophilic esophagitis (a disorder   characterized 
by infiltration of a large number of eosinophils in the 
esophagus), sclerotherapy, caustic injury, or photodynamic 
therapy.14 Dysphagia to solid foods is a common symptom. International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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EGD with biopsies should be performed in all patients with 
dysphagia to exclude neoplastic processes. After ruling 
out malignancy, benign strictures are managed by either 
  balloon or bougie dilations.9 Balloon dilators are often 
used to treat achalasia for forceful disruption of the LES. 
Bougies consist of two types: 1) mercury or   tungsten-filled 
dilator and 2) wire-guided   polyvinyl dilator. The former 
type has a tapered tip and can pass either blindly or under 
fluoroscopy. The latter type is passed over a guidewire and 
used for complex strictures.15
esophageal varices
Variceal bleeding is a serious complication of portal hyper-
tension with the mortality rate as high as 50%.16 Because 
of high mortality, nonselective beta-blockers (propra-
nolol or nadolol) have been shown to prevent or to delay 
the first episode of variceal bleeding.16 EGD is the only 
  reliable method to confirm the presence of varices. Patients 
with cirrhosis and signs of portal hypertension (platelet 
count ,140,000/mm3) should have screening endoscopy. 
  Endoscopic variceal ligation (EVL) is indicated for primary 
prophylaxis in patients who cannot tolerate beta-blockers 
(asthma). EVL has also become the treatment of choice for 
variceal hemorrhage.
Foreign bodies
Once foreign bodies are diagnosed, the timing of endoscopy 
is dependent on the risks of aspiration or perforation. Urgent 
endoscopic intervention is required to remove sharp objects 
or disk batteries that are lodged in the esophagus. Urgent 
EGD is also required to prevent aspiration when an object 
creates a high-grade obstruction. Conservative management 
is indicated when a foreign body has entered the stomach. 
If an object fails to pass the stomach within 3–4 weeks, it 
should be removed endoscopically.17
Gastric epithelial polyps
The majority of gastric epithelial polyps found during EGD 
are benign. However, adenomatous polyps have malignant 
potential. They should be completely resected. One-year 
surveillance endoscopy is reasonable to assess recurrence. 
If the result is negative, endoscopy should be repeated at 
3–5-year intervals.11
Peptic ulcer disease
Dyspepsia is a condition characterized by a variety of 
symptoms (epigastric discomfort, bloating, anorexia, early 
satiety, belching, nausea, and heartburn). It can be caused by 
peptic ulcer disease (PUD), GERD, and malignancy. GERD 
and gastric cancer will be discussed in next two sections. 
Approximately, 15% of patients with dyspepsia have PUD, 
and the majority of them are tested positive for Helicobacter 
pylori antibody.18 In patients with PUD, H. pylori infection 
should be eradicated to improve healing and to reduce the 
risk of recurrence and rebleeding. At the experienced hands, 
90% of gastroduodenal lesions can be detected by EGD.19 
For patients with previous gastrectomy as a result of PUD, 
routine endoscopic surveillance is not indicated.18
GeRD
GERD is defined as symptoms or mucosal damage produced 
by the abnormal reflux of gastric contents into the esophagus. 
Patients with mild GERD symptoms (typical heartburn or 
mild intermittent dyspepsia) may be given an initial trial of 
therapy without endoscopic evaluation. EGD is the preferred 
procedure when patients with GERD have one of the follow-
ing alarming symptoms: dysphagia, odynophagia, persistent 
or progressive heartburn symptoms while on antacid therapy, 
or weight loss.20 Sole hiatal hernia on the upper GI series is 
not an indication for EGD.
Gastric cancer
Gastric cancer is the fourth most common cancer in the world, 
only behind lung, breast, and colon cancers. However, it still 
remains the second most common cause of death from cancer 
worldwide.21 Multiple biopsies (at least seven specimens) 
of the gastric ulcers are necessary to rule out malignancy. 
It remains to be determined whether it is cost-effective to 
repeat endoscopy to verify post-treatment healing of gastric 
ulcers. At the present time, a follow-up endoscopy should be 
performed in 8–12 weeks after the initial EGD and treatment 
to document healing and repeat biopsies of any nonhealing 
ulcers.22
Ampullary adenoma
Adenoma arising at the major duodenal papilla is called 
ampullary adenoma. It can occur sporadically or in asso-
ciation with familial adenomatous polyposis (FAP) (will 
be discussed later). In order to determine the ampullary 
involvement, a side-viewing endoscope is used in addition 
to a routine forward-viewing duodenoscope. ERCP and EUS 
are   important tools in selecting patients for endoscopic or 
surgical resection (will be discussed later).23 For patients 
undergoing endoscopic resection, postprocedure endo-
scopic surveillance should be done to ensure complete 
  tissue removal and lack of disease recurrence.23 Endoscopic International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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resection techniques are not standardized and should only be 
performed by experienced endoscopists.
Nonampullary duodenal adenoma
Nonampullary duodenal adenoma (NDA) occurs outside of 
the ampulla sporadically or in association with FAP (will 
be discussed in next section). Its endoscopic appearance 
is similar to Brunner’s gland tumor, inflammatory polyp, 
carcinoid tumor, and hamartoma, thus a suspicious lesion 
should be biopsied before attempted resection.23 Before 
endoscopic resection, it is important to determine that the 
lesion does not involve the ampulla because the approach for 
evaluating an ampullary lesion is different (as noted above). 
Similar to ampullary adenomas, postprocedure endoscopic 
surveillance is indicated to verify complete resection and 
lack of occurrence.23
FAP/hereditary nonpolyposis  
colorectal cancer
The second leading cause of death in patients with FAP who 
have had colectomy is duodenal cancer.11 The risk of these 
patients developing duodenal adenocarcinoma is more than 
100-fold when compared to the general population.11 Both 
forward-viewing and side-viewing endoscopes should be 
used to detect adenomas in the duodenum, particularly in the 
periampullary region. Patients with hereditary nonpolyposis 
colorectal cancer (HNPCC) have a higher risk of developing 
cancers of the stomach and small bowel. Small bowel cancer 
in patients with HNPCC occurs at a young age (median age 
of 39), and the duodenum involves 50% of the cases.11 As a 
result, regular upper endoscopy surveillance of patients with 
FAP/HNPCC should be started around the time of colectomy 
or after the age of 30.11
IBD
Approximately 13% of patients with Crohn’s disease (CD) 
have upper GI tract involvement.24 Duodenal biopsy often 
yields more granulomas (organized collections of mac-
rophages are usually seen with CD) (40%–68%) than colonic 
biopsy.24 Hence, EGD is helpful in differentiating CD from 
ulcerative colitis (UC) in indeterminate colitis.
Percutaneous endoscopic gastrostomy
Percutaneous endoscopic gastrostomy (PEG) is an endo-
scopic procedure for placing a tube through the abdominal 
wall. Indications for PEG placement include impaired 
swallowing conditions (stroke), cancer of the oropharynx, 
larynx, and esophagus. PEG is also useful in patients with 
malignant bowel obstruction. PEG is not appropriate if 
peroral feeding is expected to resume within 30 days. 
Sometimes, the indication for PEG is debatable. In advanced 
dementia, PEG   placement does not prolong life. Ethical 
considerations should be   considered given the quality of 
life and prognosis.25
Upper GI bleeding
Patients with upper GI bleeding (UGIB) should be stabilized 
before the initiation of endoscopy. Prompt endoscopy in 
patients with UGIB is effective in diagnosing and treating 
most causes of UGIB. It is also associated with reduction in 
both blood transfusion and length of hospital stay.26 Starting 
intravenous erythromycin 30–90 min before EGD promotes 
gastric motility and emptying and significantly improves the 
mucosal visibility.26
Obscure GI bleeding
Obscure GI bleeding is defined as persistence of bleeding 
from unknown origin, despite negative initial EGD and 
colonoscopy. A study demonstrated that push endoscopy 
diagnosed 64% of the bleeding lesions in patients with 
obscure GI bleeding within the reach of the standard endo-
scope.27 As a result, a ‘second-opinion’ EGD may be indi-
cated in these patients before proceeding to WCE.
Pernicious anemia
Pernicious anemia is a form of megaloblastic anemia due 
to B12 deficiency in the setting of atrophic gastritis. Patients 
with this disorder have a 2–3-fold increase in the incidence 
of gastric cancer. Single endoscopy should be performed to 
identify prevalent lesions but routine subsequent endoscopic 
surveillance is not recommended.11
Bariatric weight loss surgery
Obesity is a major health problem that contributes to 
increased morbidity and mortality as well as to other disor-
ders worldwide. In the United States, annual cost of man-
aging obesity is approximately $100 billion.28 Weight loss 
surgery is recommended for patients with the body mass 
index (BMI) $ 40 kg/m2 or those with BMI $ 35 kg/m2 
and serious comorbid conditions.29 Patients with upper GI 
symptoms should be evaluated by EGD prior to undergoing 
bariatric surgery. A preoperative upper endoscopy is indi-
cated for patients who are having gastric banding because a 
large hiatal hernia may be a contraindication. The European International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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guidelines recommend preoperative upper endoscopy in 
all patients before surgery, regardless of whether or not 
symptoms are present.29 The rationale is that some bariatric 
surgical procedures render the stomach and duodenum inac-
cessible for upper endoscopic techniques. Nausea, vomiting, 
and abdominal pain are common symptoms commonly seen 
after bariatric surgery. However, patients with these persis-
tent problems should have an upper endoscopy because the 
symptoms may indicate the presence of marginal ulcers, 
gastrogastric fistulas, postsurgical reflux disease, or anasto-
motic obstruction.
Indications for ERCP
Choledocholithiasis
Choledocholithiasis is a disorder of gallstones in the CBD. 
Stone extraction ERCP is the treatment of choice for this con-
dition with the success rate of more than 90%.30 The overall 
complication rate and mortality rate are approximately 5% 
and less than 1%, respectively.31
Benign biliary strictures/leaks
These benign conditions result from primary sclerosing 
cholangitis (PSC), congenital bile-duct abnormalities, 
chronic pancreatitis, or postoperative complications (liver 
transplantation).30 Endoscopic dilation is achieved by a 
graduated catheter, balloon, stent placement, or combination 
of interventions. Dominant strictures of patients with PSC 
should also undergo endoscopic brushing and biopsy for 
assessment of malignancy.
Pancreatic ductal leaks
Pancreatic ductal leaks occur as a result of acute pancreatitis, 
chronic pancreatitis, trauma, or surgical injury. Pancreatic 
leaks can lead to pancreatic ascites and pseudocyst formation. 
The leaks can be ‘bridged’ with transpapillary stents.30
Sphincter of Oddi dysfunction
Sphincter of Oddi dysfunction (SOD) is a condition of biliary 
colic resulting from the obstruction of bile and pancreatic 
juice flow. Patients with this disorder can have abnormal liver 
chemistries, dilated bile duct, or both. The gold standard to 
diagnose SOD is biliary manometry, which is performed 
during ERCP.30 Biliary sphincterotomy alleviate pain in the 
majority of patients. SOD manometry has an increased rate 
of pancreatitis and should be performed by experienced 
endoscopists.
Recurrent acute pancreatitis
If other imaging modalities of patients with recurrent acute 
pancreatitis are equivocal, ERCP should be done to evaluate 
the ductal anatomy along with bile analysis for microlithia-
sis. Endoscopic sphincterotomy without cholecystectomy 
is a viable option for patients with microlithiasis.30
Chronic pancreatitis
Both ERCP and EUS are useful for diagnosing CP, but ERCP 
should be reserved for patients in whom the diagnosis has 
not been established by less-invasive studies.32
Pancreatic fluid collections
ERCP can drain pancreatic fluid collections, such as acute 
pseudocyst, chronic pseudocysts, and pancreatic necrosis. 
Fluid collections communicating with the PD are drained 
via the transpapillary approach, while noncommunicating 
collections are amenable to the transmural (transgastric or 
transduodenal) therapy. The success rates for transpapillary 
and transmural routes are .90% and .80%, respectively.30 
Acute and chronic pseudocysts will be further discussed in 
the EUS section.
Bariatric weight loss surgery
Bariatric weight loss surgery has been discussed above 
in the EGD section. Postoperative rates for gallstones are 
high (22%–71%), and cholecystectomy was performed in 
7%–41% of patients who underwent bariatric surgery.29 The 
rates of choledocholithiasis in these patients are unknown. 
ERCP is challenging due to altered anatomy. According to a 
small study, ERCP with successful papilla cannulation was 
only achieved in 66% of patients.29
Intraductal papillary mucinous neoplasm
Intraductal papillary mucinous neoplasm (IPMN) is defined 
as papillary proliferations of pancreatic mucin-producing 
epithelial cells with/without excessive mucin hypersecretion 
and/or cystic ductal dilation. (Please refer to the EUS sec-
tion for further discussion.) On ERCP, the pathognomonic 
for IPMN is the finding of mucus extruding from a patulous 
ampulla.33 Pancreatographic findings during ERCP suggest-
ing IPMN are segmental or diffuse dilatation of the main 
PD or focal side-branch dilatation. Sometimes filling defects 
in the main PD (caused by mucus) can be differentiated 
from stones by their transient nature when passed with a 
guidewire.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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Ampullary adenoma
Before endoscopic resection of an ampullary adenoma, the 
extent of biliary and pancreatic involvement is evaluated 
by ERCP. Some authors recommend surgical resection if 
there is evidence of intraductal extension; other authors still 
favor endoscopic resection as long as the extension is ,1 cm 
because, at this level, the invading tissue can be endoscopi-
cally ablated.23
Cholangiocarcinoma
Cholangiocarcinoma is a cancer of the bile ducts. It is rare 
and highly lethal due to local metastases at presentation. 
The common risk factor is PSC, which is closely associated 
with UC. Patients with unresectable cholangiocarcinoma and 
jaundice should undergo ERCP for stent placement.34
Pancreatic malignancy
Pancreatic cancer is the fourth leading cause of death in the 
United States.35 The pathognomonic finding of pancreatic 
head cancer on ERCP is the ‘double-duct’ sign, biliary and 
pancreatic ductal strictures with proximal dilation. With 
recent advances in other noninvasive pancreatic imaging 
modalities, preoperative ERCP does not add further staging 
information and may result in complications (pancreatitis 
and perforation) that make surgery more difficult. However, 
for patients with cholangitis, severe pruritus, or patients who 
are not fit for surgery, ERCP with biliary stenting should be 
performed to relieve obstruction.34
Indications for EUS
esophageal cancer/CRC
These cancers are staged according to the ‘Tumor, Node, 
and Metastasis’ system. Accurate staging is important for 
therapeutic decision-making and prognostication. Staging 
with EUS is more accurate than computed tomography (CT) 
in these types of cancers.13
Gastric carcinoma/lymphoma
Similar to esophageal cancer, EUS is superior to both CT 
and intraoperative surgical assessment for staging gastric 
carcinoma and lymphoma. It is also useful in monitoring 
response to therapy in patients with lymphoma.36
Mediastinal adenopathy
Mediastinal adenopathy may be detected by CT, by chest 
X-ray, or by the presence of extrinsic compression of the 
esophagus detected during EGD. Mediastinal adenopathy is 
caused by both benign processes (sarcoidosis, tuberculosis, 
and histoplasmosis) and malignant processes (metastatic 
cancer and lymphoma). EUS-FNA avoids mediastinoscopy 
or thoracotomy and increases the yield of malignancy. 
Therefore, EUS-FNA is the preferred procedure for tissue 
sampling of posterior mediastinal lymph nodes or lesions 
seen on cross-sectional imaging.37
Pancreatic malignancy
EUS and EUS-FNA are useful adjunctive techniques for 
the diagnosis and staging of pancreatic malignancies. In 
patients with unresectable carcinoma, EUS allows patient 
selection for stent placement and EUS-guided celiac plexus 
neurolysis.34
Pancreatic cystic lesions
Pancreatic cystic lesions are a frequent incidental finding 
due to the increased use of high resolution abdominal 
radiographic imaging. These lesions are classified into 
either benign or malignant cysts, depending on whether 
they have the malignant potential. The benign cyst is 
pseudocyst, whereas the malignant cystic lesions consist of 
serous cystadenoma, mucinous cystadenoma, IPMN, and 
solid pseudopapillary neoplasm.33 EUS and EUS-guided 
procedures (EUS-FNA, EUS-guided drainage, and EUS-
guided celiac plexus blockage) play an important role 
in diagnosing and managing pancreatic cystic lesions. 
Some EUS features can differentiate a certain type of 
cystic lesion from others. EUS-FNA of the cystic lesions 
provides further information on the etiology of the cysts. 
The different types of pancreatic cystic lesions include 
the following:
1.  Acute/chronic pseudocyst: A pseudocyst is a collection 
of pancreatic juice enclosed by a wall of nonepithe-
lialized granulation tissue. Acute pseudocyst, which 
requires at least 4 weeks to form, arises from acute 
pancreatitis; chronic pseudocyst develops as a result of 
chronic pancreatitis. EUS-guided drainage of pseudo-
cysts has similar outcomes to surgical drainage. The 
indications for drainage are abdominal pain, gastric 
outlet obstruction, early satiety, weight loss, jaundice, 
infection, or progressive enlargement, even if asymp-
tomatic.32 Long-term pain management in patients with 
chronic pancreatitis can be difficult. EUS-guided celiac 
plexus blockage has shown to be more effective, has 
longer duration, and is less expensive than CT-guided 
plexus blockage.32
2.  Serous cystadenoma: Serous cystadenoma originates 
from centroacinar cells of the pancreatic exocrine system. International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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The lesion consists of many small cystic spaces separated 
by thin septae. Hence, on EUS, it has been described 
as having a ‘honeycomb’ or ‘sponge-like’ appearance. 
Malignant progression is extremely rare, so surveillance 
is unnecessary.33
3.  Mucinous cystadenoma: Mucinous cystadenoma is 
usually solitary, occurring exclusively in women, and 
almost always found in the pancreatic body or tail. The 
presence of ovarian-type stroma is required to diagnosis 
mucinous cystic neoplasm. Fluid obtained by EUS-FNA 
is typically viscous and positive for mucin. On EUS, it 
appears macrocystic and has peripheral calcifications. 
The rates of malignancy are ranged from 6% to 27%.38 
The international consensus guidelines recommend sur-
gical resection in patients who are fit for surgery.39 No 
surveillance is required after resection in patients with 
benign and noninvasive lesions.
4.  IPMN: IPMN is a premalignant lesion involving mucin-
producing epithelial cells of the PDs. IPMN affects 
men and women equally, usually locates in the head 
of the pancreas, and may be multiple. IPMN is further 
subdivided into three types: main-duct IPMN, branch-
duct IPMN, and mixed-duct IPMN. Main-duct IPMN 
is characterized by dilation of the main duct (more than 
1 cm), whereas branch-duct IPMN consists of the side-
branch mucinous cyst without main duct involvement. 
Mixed-duct IPMN has features of both branch-duct 
and main-duct IPMNs. The prevalence of malignancy 
in main/mixed-duct IPMN is significantly higher than 
branch-duct IPMN. According to a pooled analysis, 70% 
and 43% of main/mixed-duct IPMN versus 25% and 15% 
of branch-duct IPMN have carcinoma in situ and invasive 
carcinomas, respectively.39 As a result, the guidelines 
recommend resection for all patients with main/mixed-
duct IPMNs who are good surgical candidates and have 
reasonable life expectancy.39 For branch-duct IPMN, 
resection is suggested for those who have symptoms 
associated with the cyst (pain or pancreatitis), cystic 
lesion more than 30 mm, and intramural nodules or 
cyst fluid cytology suspicious/positive for malignancy. 
Otherwise, a ‘watch and see’ approach with frequent 
surveillance is recommended for ‘low-risk’ branch-duct 
IPMN. If the cyst is less than 1 cm and if imaging studies 
show stability after 1 year, then the interval of surveil-
lance can be lengthened to 2 years. However, emerging 
evidence indicates this ‘low-risk’ entity may be associ-
ated with synchronous and/or metachronous pancreatic 
ductal carcinomas.40 As a result, our understanding of 
the natural history of ‘low-risk’ branch-duct IPMN is 
still an enigma. Several EUS findings can distinguish the 
above three subtypes, which include the main duct and/or 
branch-duct dilation(s), septation, and mural   nodularity 
(solid components within the cystic lesion). Mural 
nodularity is a harbinger of malignancy. High cystic 
carcinoembryonic antigen level obtained by   EUS-FNA 
may also indicate malignancy.
5.  Solid pseudopapillary neoplasm: Solid   pseudopapillary 
neoplasm is a rare pancreatic cyst lesion with low 
malignant potential. It is commonly seen in young 
women (,35 years). The characteristics on EUS are 
well-demarcated, echo-poor, and solid-appearing mass.33 
Fluid analysis by EUS-FNA can diagnose 75% of cases.38 
Because of the indolent nature of this lesion, even with 
metastases, surgery is still recommended.
Submucosal tumors
Submucosal tumors are divided into two groups. The more 
common group is referred to as gastrointestinal stromal 
tumors, and the less common group includes lipomas, 
schwannomas, hemangiomas, leiomyomas, and their malig-
nant counterparts (leiomyosarcoma). The diagnosis of these 
tumors is difficult by standard imaging. EUS can suggest the 
nature of a submucosal tumor by determining the layer of 
origin and echotexture of the lesion. Tumor size, an irregular 
border, echogenic foci, and cystic spaces are independently 
associated with malignancy.36
Ampullary adenoma/NDA
For ampullary adenoma, EUS and intraductal EUS (a small 
EUS probe passing inside the pancreatobiliary systems) 
allow us to evaluate periampullary lymph nodes, to select 
patients for endoscopic versus surgical resection, and to guide 
surgical therapy.23 For NDA, EUS allows us to determine the 
relationship of the polyp to the pancreaticobiliary tree when 
side-viewing examination is uncertain. In addition, EUS can 
also determine whether endoscopic removal is feasible when 
biopsy shows HGD.23
Ampullary carcinoma
Ampullary carcinoma is a relatively rare cancer that 
accounts for approximately 0.2% of GI malignancies.41 It 
is suspected when a patient presents with obstructive jaun-
dice, and abdominal imaging studies show pancreatic and 
biliary ductal dilatation. EUS allows not only more accurate 
diagnosis and staging of these lesions than CT, but it also 
permits tissue biopsies and FNA sampling.34 In addition, International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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EUS selects appropriate patients for   undergoing local 
resection instead of pancreaticoduodenectomy (Whipple 
procedure).
IBD
For patients with CD, EUS can accurately assess perianal 
fistula and abscess. EUS is also useful in monitoring medical 
and surgical therapy for CD perianal fistulae.24
Indications for WCE/DBE
Obscure GI bleed
Two modalities have complementary roles and are not mutu-
ally exclusive. The most common indication of WCE is for 
the evaluation of obscure GI bleeding (unknown bleeding 
origin after initial EGD and colonoscopy). A cost-analysis 
study showed that the initial DBE approach is more cost-
effective.42 However, because DBE is potentially associated 
with serious complications, such as pancreatitis and bowel 
perforation, the authors advocate using CE-directed DBE 
approach because this would reduce complications and 
decreased utilization of endoscopic resources.42
Other indications
Other indications for WCE include CD, ulcers, polyps, 
foreign bodies, infiltrative diseases, and imaging abnormali-
ties.6 It should be emphasized that in patients with CD and 
suspected strictures, WCE is contraindicated.
Indications for colonoscopy
Acute colonic pseudo-obstruction
Acute colonic pseudo-obstruction (ACPO) is characterized 
by massive colonic dilation in the absence of mechani-
cal obstruction. The symptoms include nausea, vomiting, 
abdominal pain, constipation, and paradoxically diarrhea. 
Spontaneous perforation occurs in 3%–15% of patients with 
a mortality rate of 50% or higher. Endoscopic decompres-
sion should be performed if conservative therapy fails or if 
neostigmine is contraindicated.43
Chronic diarrhea
Lower endoscopy can play a pivotal role in the evaluation of 
patients with chronic diarrhea. Endoscopy with colonic biopsy 
is helpful in ruling out IBD, ischemic colitis, collagenous and 
microscopic colitis, and neoplastic disease. When patients 
with human immunodeficiency virus and chronic diarrhea 
have negative basic stool test, lower endoscopy with biopsy is 
indicated to rule out infectious causes. Mucosal biopsies are 
the ‘gold standard’ to establish graft-versus-host-disease after 
bone marrow transplantation and to rule out other infections 
and pathologies. Upper GI evaluation may ensue when lower 
GI workup for chronic diarrhea is negative.44
Ampullary adenoma/NDA
Studies indicate that patients with sporadic ampullary ade-
nomas or duodenal adenomas are at greater risk for CRC.23 
Screening colonoscopy should be offered to patients with 
these polyps.
IBD
Mucosal biopsy during colonoscopy with ileoscopy is invalu-
able in the evaluation of IBD and the differentiation of UC 
from CD. Endoscopy along with other diagnostic modalities 
can distinguish CD from UC in $85% of patients.24 Surveil-
lance colonoscopy every 1–2 years starting 8–10 years after 
disease onset is recommended for patients with CD and UC. 
Biopsy specimens are obtained in all four quadrants every 
10 cm from the cecum to the rectum. Colectomy should be 
performed when there is the presence of HGD or multifocal 
LGD in a flat mucosa. Colonic strictures in patients with 
UC are considered malignant until proven otherwise. If a 
stricture is unable to be assessed thoroughly, colectomy is 
indicated.24 Chronic obstruction due to fibrotic strictures can 
be managed by endoscopic balloon dilation. For patients 
with CD undergoing partial colectomy or partial ileocolec-
tomy, recurrence rates range from 70% to 90% after 1 year 
of surgery.24 Therefore, colonoscopy is recommended at 
6–12 months after surgery to identify patients who may 
benefit from medical therapy.
Colorectal screening and surveillance
CRC is the second leading cause of cancer-related deaths 
in the United States. Therefore, it is important for primary 
care physicians to understand the role of CRC screening 
and surveillance. The following recommendations for early 
detection of CRC and adenomatous polyps in average-risk 
adults (aged 50 years and older) are based on the most recent 
published guideline by the ACS.45 For CRC screening and 
surveillance in high-risk patients (family or personal history 
of CRC, IBD, or FAP/HNPCC), please refer to the actual 
guidelines.45 Screening tests are divided into two catego-
ries: fecal tests (guaiac fecal occult blood test (gFOBT), 
fecal immunochemical test (FIT), and stool-based DNA 
(sDNA)) and structural exams (FS, colonoscopy, double 
contrast barium enema (DCBE), and computerized topog-
raphy colonography (CTC)). The appropriate test to be used International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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depends on the individual’s preference and local resources. 
Patients should understand that positive findings with less 
invasive tests require follow-up colonoscopy.
1.  gFOBT: Annual screening with gFOBT has high sensitiv-
ity for detecting CRC in average-risk adults aged 50 years 
and older. Two to three stool samples from each of three 
consecutive bowel movements at home are collected. 
Guaiac testing following digital rectal exam in the office 
and rehydrated specimen (adding distilled water to the dry 
sample) are not recommended. Patients are instructed to 
avoid aspirin or NSAIDS 7 days prior to testing, unless 
they are on a cardioprotective regimen. Because the 
gFOBT is based on the detection of peroxidase, certain 
foods (citrus fruits, turnip, horseradish, and red meats) 
should also be avoided 3 days before testing. If any test 
is positive, a follow-up colonoscopy is recommended. 
Primary practitioners should emphasize the importance of 
annual screening in order to achieve the fullest potential 
of this test.
2.  FIT: FIT detects human hemoglobin, which eliminates 
the need of a restricted diet before testing as with gFOBT. 
In addition, FIT requires fewer specimens (2 versus 3) 
and simpler sampling procedure (brush versus spatula 
method) when compared with guaiac-based testing. Cur-
rently, there are no data to support the superiority of FIT 
over gFOBT. However, the likelihood of test completion 
appears to be greater with FIT due to its simplicity.
3.  sDNA: Adenoma and CRC that contained altered DNA 
are shed and passed in feces. The abnormal DNA is iso-
lated and detected by a multiple-marker panel. Because 
sDNA is an evolving technology, the screening interval 
between negative tests remains to be determined.
4.  FS: FS will be discussed later.
5.  Colonoscopy: The evidence to support screening colonos-
copy is substantial. At present, screening colonoscopy 
every 10 years is recommended.
6.  DCBE: As the name implies, the entire colon is dis-
tended with air and barium via a rectal catheter. Multiple 
radiographs are acquired during a 20–40-min procedure. 
Because no sedatives are given, patients can return to 
work after the examination. The acceptability of DCBE 
may be limited by requiring a 24-h bowel preparation, 
and some patients may experience mild to moderate 
discomfort during and after the procedure. In addition, 
DCBE has lower sensitivity than colonoscopy and pro-
vides no opportunity for biopsy. A follow-up colonoscopy 
is required for any polyps greater than 6 mm on DCBE. 
A 5-year interval screening is recommended.
7.  CTC: Thin CT images of the large intestines are acquired 
in 10-min procedure. Bowel preparation is similar to 
colonoscopy. The colon is distended by room air or 
carbon dioxide via a catheter in the rectum. No sedation 
is required during the procedure. If the CTC shows any 
polyps larger, equal to 6 mm or greater, colonoscopy 
should be offered. CTC is appropriate for those patients 
who decline colonoscopy or when colonoscopy is con-
traindicated. Screening interval is 5 years for average-risk 
patients at age of 50.
8.  CRC: Colonoscopy allows for multiple endoscopic biopsies 
necessary to confirm CRC. Malignant   obstruction can be 
managed effectively for palliation, or as a bridge to surgery 
with self-expandable metal stent or laser therapy. HGD and 
malignant pedunculated polyps with favorable histologic 
features can be adequately treated with endoscopic resec-
tion. Surveillance should consist of a follow-up endoscopy 
within 3–6 months after resection.46
Constipation
Chronic constipation is associated with an increased risk of 
colon cancer.47 For this reason, patients with constipation who 
are above 50 years and have not had a colon cancer screening 
should have a colonoscopy.47 Patients and physicians should 
be aware that Medicare (health insurance program for the 
elderly administered by the US government) might not reim-
burse for colonoscopy if the sole indication is constipation.
Lower GI Bleeding
Lower GI bleeding (LGIB) may present as occult fecal blood, 
iron deficiency anemia, melena, intermittent hematochezia, 
or acute bleeding. Colonoscopy is effective in the diagnosis 
and treatment of LGIB. If a bleeding source is not identified 
by colonoscopy, EGD should be performed to rule out upper 
GI bleeding.48
Indications for FS
Colorectal screening
Patients with distal adenomas have an increased risk of 
advanced proximal neoplasia. If adenomas are found at FS, 
colonoscopy should be performed for complete examination 
of the colon. For surveillance of average-risk patients, either 
FS alone or FS with annual gFOBT or FIT is recommended 
every 5 years.45
Other indications
Because of low malignant risk in younger patients (,50 years) 
with suspected distal colonic disease, FS should be   considered International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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instead of colonoscopy. In patients with IBD, FS is preferred 
when colonoscopy is considered high risk (fulminant colitis). In 
addition, when there is an exacerbation in patients with UC, FS is 
useful in evaluating   superimposed   infections (  cytomegalovirus, 
Clostridium difficile) or   condition (  ischemic colitis).24
Conclusion
In the rapidly changing field of endoscopy as well as increasing 
referrals to OAE centers by nongastroenterologists, primary care 
practitioners should have an updated understanding of new endo-
scopic technologies and its indications in order to save resources, 
to provide optimal care with the least risk, and to facilitate effec-
tive communication between different specialties.
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